-
Mashup Score: 0
The phase 3 FAST-Forward trial reported outcomes for 26 and 27 Gy schedules delivered in 5 fractions over 1 week versus 40 Gy in 15 fractions over 3 weeks in 4000 patients. We discuss concerns raised by the radiotherapy community in relation to implementing this schedule.
Source: Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Miranda Kleijn, PhD, Agendia, Amsterdam, Netherlands, shares the findings of a comparative assessment of MammaPrint and BluePrint genetic assay results…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Denosumab is a monoclonal antibody targeting RANK ligand (RANKL). Evidence has implicated RANKL in the development of BRCA1-associated breast cancer…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Judy Garber, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, shares the findings of a Phase II randomized study (NCT01196936) of…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Miranda Kleijn, PhD, Agendia, Amsterdam, Netherlands, discusses the FLEX study (NCT03053193), a large-scale, prospective, observational trial of patients with stage…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3EHA 2021 | VJHemOnc - 3 year(s) ago
1:49 Results from MANIFEST Phase II study of pelabresib for anemia associated with myelofibrosis Srdan Verstovsek • 9 Jun 2021 2:40 Benefits of pelabresib with ruxolitinib for treatment naïve myelofibrosis Srdan Verstovsek • 9 Jun 2021 1:30 The safety profile of imetelstat in myeloid malignancies John Mascarenhas • 10 Jun 2021 1:27 JAKARTA and JAKARTA2: OS and PFS analysis of…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
We're tuned in to Stefan Constantinescu's fascinating talk on functional consequences of mutations in MPNs at #EHA2021 👨⚕️ 🎇 You can find more EHA 2021 updates on MPNs here: https://t.co/yACgMBzrOc 🎇 @VJHemOnc @EHA_Hematology #MyeloproliferativeNeoplasms #HemOnc#MPNsm #ClinOnc https://t.co/IHqNR5Hfsz
-
-
Mashup Score: 0
Giacomo Bregni, MD, Jules Bordet Institute, Brussels, Belgium, gives an overview of the Phase II REGINA trial (NCT04503694) which is…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 05-year DMFS outcomes in the NBREaST II trial - 3 year(s) ago
Miranda Kleijn, PhD, Agendia, Amsterdam, Netherlands, shares the 5-year follow-up results of the NBREaST II trial, assessing the use of…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Genomic testing in early breast cancer: MammaPrint & BluePrint - 3 year(s) ago
Genomic testing in early-stage breast cancer can give useful insights above and beyond the clinical and pathological features. Several gene…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Optimizing gemcitabine in metastatic TNBC - 3 year(s) ago
Nathan M. Merrill, PhD, University of Michigan, Ann Arbor, MI, outlines the findings of a study which investigated the optimization…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Five-fraction Radiotherapy for Breast Cancer: FAST-Forward to Implementation. Read the #OpenAccess paper here: https://t.co/4dRXUbjVGE @RCRadiologists @achoud72 #ClinOnc #bcsm https://t.co/ijyDP60dLP